



March 2, 2018

Zosano Pharma Announces Issuance of New U.S. Patent Covering M207 as an Acute Treatment for Migraine

Patent extends proprietary position of M207 to 2037

FREMONT, Calif., March 02, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corp. (NASDAQ:ZSAN) ("Zosano" or the "Company") a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied Microarray ("ADAM™") technology, today announced that the previously announced Notice of Allowance of our patent application titled "Method of Rapidly Achieving Therapeutic Concentrations of Triptans for Treatment of Migraines" has resulted in the issuance of a U.S. patent 9,918,932. The inventors were Dr. Mahmoud Ameri, Dr. Don Kellerman, Dr. Yi Ao, and Dr. Peter Dadonna, all of whom are current or former employees of Zosano. In February 2017, Zosano reported positive pivotal data from our Zotrip Phase 2/3 trial, in which subjects treated with the 3.8mg dose of M207 achieved statistical significance on the co-primary endpoints. The newly issued patent contains claims generated from formulation, preclinical and clinical studies, and highlights the unique aspects of the Zosano technologies and their applicability for treatment of migraine.

"We are pleased to have this important expansion of our patent estate for M207," said John Walker, Chairman and Chief Executive Officer of Zosano. "This issuance supports our intellectual property strategy for our ADAM technology, and specifically M207. We intend to pursue similar patent coverage for future products that Zosano develops internally, and in future partnerships."

Zosano's patent estate additionally includes other granted U.S. and foreign patents and pending patent applications covering our ADAM technology, including our microneedle technology, drug formulations, methods of use and applicators.

About M207

M207 is our proprietary formulation of zolmitriptan delivered utilizing Zosano's proprietary Adhesive Dermally-Applied Microarray, or ADAM technology. Zosano's ADAM technology consists of titanium microprojections coated with drug, and in the case of M207, our formulation of zolmitriptan. Our ADAM technology delivers drug by penetrating the stratum corneum and allowing drug to be absorbed into the microcapillary system of the skin. In February 2017, the Company announced statistically significant results from the ZOTRIP trial, which demonstrated that the 3.8mg dose of M207 met both co-primary endpoints, achieving pain freedom and most bothersome symptom freedom at 2 hours.

About Zosano Pharma

Zosano Pharma Corporation is a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using our proprietary Adhesive Dermally-Applied Microarray, or ADAM technology. The Company recently announced positive results from our ZOTRIP study that evaluated M207, which is our proprietary formulation of zolmitriptan delivered via our ADAM technology, as an acute treatment for migraine. Zosano is focused on developing products where rapid administration of established molecules with known safety and efficacy profiles provides an increased benefit to patients, for markets where patients remain underserved by existing therapies. The Company anticipates that many of its current and future development programs may enable the Company to utilize a regulatory pathway that would streamline clinical development and accelerate the path towards commercialization. Learn more at www.zosanopharma.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding the timing of expected clinical development milestones, sufficiency of our capital resources and need for future funding and other future events and expectations. Readers are urged to consider statements that include the words "may," "will," "would," "could," "should," "might," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," "unaudited," "approximately" or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict and actual outcomes may differ materially. These include risks and uncertainties, without limitation, associated with the process of discovering, developing and commercializing products that are safe and effective for use as human therapeutics, risks inherent in the effort to build a business around such products and other risks and uncertainties described under the heading "Risk Factors" in the

Company's most recent annual report on Form 10-K.. Although we believe that the expectations reflected in these forward-looking statements are reasonable, we cannot in any way guarantee that the future results, level of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. All forward-looking statements are based on information currently available to Zosano and Zosano assumes no obligation to update any such forward-looking statements.

Zosano Contact:

Georgia Erbez
Chief Business Officer and
Chief Financial Officer
510-745-1200